{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:02:54Z","timestamp":1780329774945,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107150","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:53:51Z","timestamp":1773942831000},"page":"107150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Validation of a new diagnostic ELISA to detect anti-JCV antibodies in serum of patients with multiple sclerosis considering or receiving treatment with natalizumab"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-3157","authenticated-orcid":false,"given":"Fred","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-3521","authenticated-orcid":false,"given":"Rafa\u0142","family":"Derlacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4008-7635","authenticated-orcid":false,"given":"Marc-Andre","family":"Frese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-3046","authenticated-orcid":false,"given":"Thomas","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Schelcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107150_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101972","article-title":"Dynamic expression of JC virus in urine and its relationship to serostatus","volume":"41","author":"Berger","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107150_bib0002","unstructured":"European Medicines Agency, 2025a. TYSABRI\u00ae (natalizumab). Summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf (accessed 11 December, 2025)."},{"key":"10.1016\/j.msard.2026.107150_bib0003","unstructured":"European Medicines Agency, 2025b Tyruko\u00ae (natalizumab). Summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tyruko-epar-product-information_en.pdf (accessed 11 December, 2025)."},{"key":"10.1016\/j.msard.2026.107150_bib0004","unstructured":"European Medicines Agency, 2023. Tyruko European public assessment report. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tyruko-epar-public-assessment-report_en.pdf (accessed 9 May 2024)."},{"key":"10.1016\/j.msard.2026.107150_bib0005","series-title":"Stratify JCV DxSelect\u2122. Instructions for Use","year":"2015"},{"key":"10.1016\/j.msard.2026.107150_bib0006","series-title":"IMMUNOWELL\u2122 JCV IgG Test. Instructions for Use","year":"2024"},{"key":"10.1016\/j.msard.2026.107150_bib0007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamaneurol.2022.5007","article-title":"Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial","volume":"80","author":"Hemmer","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107150_bib0008","first-page":"807","article-title":"JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level","volume":"10","author":"Lanzillo","year":"2014","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.msard.2026.107150_bib0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2026.107150_bib0011","first-page":"179","article-title":"John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy","volume":"41","author":"Pietropaolo","year":"2018","journal-title":"New. Microbiol."},{"key":"10.1016\/j.msard.2026.107150_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ane.12840","article-title":"The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy","volume":"136","author":"Reuwer","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2026.107150_bib0013","first-page":"650","article-title":"StratifyJCV Serum anti-JCV antibody assay for patients treated with natalizumab: quality control of sample analysis by Unilabs","volume":"29","author":"Svendsen","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107150_bib0014","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","article-title":"Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice","volume":"5","author":"Trevethan","year":"2017","journal-title":"Front. Public Health"},{"key":"10.1016\/j.msard.2026.107150_bib0016","unstructured":"US Food and Drug Administration, 2023a. Tyruko\u00ae (Natalizumab-sztn). Prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761322s000lbl.pdf (accessed 11 December 2025)."},{"key":"10.1016\/j.msard.2026.107150_bib0015","unstructured":"US Food and Drug Administration, 2025b. Tysabri\u00ae (Natalizumab). Prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125104s984lbl.pdf (accessed 11 December 2025)."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:23:07Z","timestamp":1780327387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"alternative-id":["S2211034826001860"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107150","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a new diagnostic ELISA to detect anti-JCV antibodies in serum of patients with multiple sclerosis considering or receiving treatment with natalizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107150"}}